Statistically significant correlations of per cent change in biomarker levels from baseline, with clinical end points*
| Treatment | Efficacy parameter | r Value | p Value |
|---|---|---|---|
| *Only statistically significant correlations are shown. | |||
| ACR20, American College of Rheumatology 20% improvement; ACR50, American College of Rheumatology 50% improvement; DAS28, Disease Activity Score based on 28 joints; ICAM-1, intracellular adhesion molecule-1; IL8, interleukin 8; SHS, Sharp score with the van der Heijde modification. | |||
| Infliximab (n = 11) | |||
| Week 14 | |||
| ICAM-1 | ACR50 | 0.71 | 0.014 |
| IL8 | ACR20 | −0.66 | 0.027 |
| IL8 | ACR50 | −0.59 | 0.052 |
| Osteocalcin | SHS | −0.78 | 0.004 |
| Week 16 | |||
| IL8 | ACR50 | −0.74 | 0.008 |
| Etanercept (n = 12) | |||
| Week 14 | |||
| IL8 | DAS28 | −0.59 | 0.041 |
| Osteocalcin | DAS28 | 0.69 | 0.011 |